Our Pricing

Understanding Wegovy Long-Term Side Effects for Weight Loss

Published on: June 03, 2026

Understanding wegovy long-term side effects uk is essential before starting semaglutide treatment. At Cured Pharmacy, our UK-registered clinical team has supported thousands of patients through their weight loss journey, and we've compiled this evidence-based guide to help you make informed decisions about your health.

What Are the Most Common Wegovy Long-Term Side Effects UK Patients Experience?

Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. The most frequently reported long-term side effects involve the gastrointestinal system, as semaglutide slows gastric emptying to promote satiety and reduce appetite.

In the STEP 1 trial involving 1,961 participants over 68 weeks, approximately 74% of patients experienced at least one gastrointestinal event [1]. The most common included nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%). Importantly, most of these effects were mild to moderate in severity and typically diminished over time as patients adapted to treatment.

Long-term data from extended STEP trials show that gastrointestinal side effects tend to peak during dose escalation phases and substantially decrease after 20-30 weeks of continuous treatment [2]. Our superintendent pharmacist Tarun Kumar notes that patients who follow the gradual dose titration schedule experience fewer persistent symptoms than those who escalate too rapidly.

How Long Do Wegovy Side Effects Typically Last?

The duration of Wegovy side effects varies considerably between individuals, but clinical trial data provides useful guidance. Nausea, the most commonly reported adverse effect, typically emerges within the first few doses and peaks during the initial 8-12 weeks of treatment [1].

Most patients find that gastrointestinal symptoms improve significantly between weeks 12 and 20, particularly if they maintain consistent dosing and avoid trigger foods. In the STEP trials, discontinuation rates due to adverse events were highest in the first 20 weeks, after which they decreased substantially [2].

However, some patients may experience intermittent symptoms throughout treatment, particularly after dose increases. The standard Wegovy titration schedule involves five dose escalations over 16-20 weeks, and mild nausea or changes in bowel habits may temporarily recur with each increase before settling again.

Managing Persistent Symptoms

If side effects persist beyond 20 weeks or worsen over time, this warrants clinical review. Your UK prescriber may recommend maintaining your current dose longer before escalating, adjusting injection timing, or reviewing your dietary patterns. At Cured Pharmacy, all patients have access to ongoing clinical support throughout their treatment journey, ensuring any concerns are addressed promptly by our UK-registered prescribers.

Wegovy Side Effects After Stopping: What to Expect

When discontinuing Wegovy, patients often wonder about withdrawal effects and weight regain. Semaglutide has a half-life of approximately one week, meaning it takes 4-5 weeks for the medication to be fully eliminated from your system after your last injection [3].

During this washout period, you may notice a gradual return of appetite as the GLP-1 receptor activity diminishes. Clinical data from the STEP 1 extension study showed that participants who stopped treatment regained approximately two-thirds of their lost weight within one year of discontinuation [4]. This isn't a side effect per se, but rather reflects the chronic nature of obesity and the need for ongoing management strategies.

Some patients report temporary digestive changes as their gastric emptying returns to baseline speed. You might experience increased hunger, faster digestion, or changes in satiety signals. These are normal physiological adjustments rather than adverse reactions. If you're considering stopping Wegovy, discuss transition strategies with your prescriber to maintain your weight loss achievements through lifestyle modifications or alternative treatments.

Serious Long-Term Side Effects and Safety Monitoring

While most Wegovy side effects are mild and manageable, certain serious adverse events require awareness and monitoring. Pancreatitis has been reported in approximately 0.2% of patients in clinical trials, presenting as severe abdominal pain that may radiate to the back [1]. If you experience persistent, severe abdominal pain, you should seek immediate medical attention and discontinue Wegovy until assessed.

Gallbladder-related problems, including cholelithiasis (gallstones) and cholecystitis, occurred in 1.6% of Wegovy patients versus 0.7% of placebo patients in STEP trials [2]. Rapid weight loss itself increases gallstone risk, making it difficult to separate medication effects from weight reduction effects. Symptoms include right upper abdominal pain, particularly after fatty meals, nausea, and fever.

Thyroid C-cell tumours have been observed in rodent studies at high doses, leading to a black box warning in some jurisdictions [5]. However, no causal relationship has been established in humans during post-marketing surveillance. Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will screen for these conditions during your clinical assessment.

Cardiovascular Safety Profile

Long-term cardiovascular safety data for semaglutide is reassuring. The SELECT trial demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease over a median follow-up of 40 months [6]. This suggests potential cardiovascular benefits beyond weight loss, though Wegovy is not licensed specifically for cardiovascular risk reduction in the UK.

Is Wegovy Safe Long Term for Continuous Use?

Current evidence supports the long-term safety of Wegovy for chronic weight management when used under medical supervision. The longest randomised controlled trial data extends to 104 weeks (approximately 2 years), with open-label extension studies providing safety data up to 3 years [4].

In these extended studies, the safety profile remained consistent with shorter-term trials, with no new safety signals emerging with prolonged use. Discontinuation rates due to adverse events were highest in the first 20 weeks and remained stable thereafter, suggesting that patients who tolerate initial treatment generally continue to do so long-term [2].

However, Wegovy is a relatively new medication for weight management, licensed in the UK only since 2023. While clinical trial data is robust within the 2-3 year timeframe, we lack decades of real-world safety data that exists for older medications. The MHRA continues post-marketing surveillance, and healthcare professionals report any suspected adverse reactions through the Yellow Card scheme.

Ongoing Monitoring Requirements

Patients on long-term Wegovy should have regular clinical reviews to monitor efficacy, tolerability, and any emerging concerns. At Cured Pharmacy, we recommend clinical check-ins at 3 months, 6 months, and then every 6-12 months during ongoing treatment. Your prescriber will assess weight loss progress, side effect profile, and whether continued treatment remains appropriate for your individual circumstances.

Starting Wegovy Safely: How Cured Pharmacy Supports Your Journey

Understanding potential side effects is crucial, but so is accessing genuine UK-licensed medication with proper clinical oversight. At Cured Pharmacy, all Wegovy prescriptions begin with a comprehensive online consultation completed by UK-registered prescribers who assess your medical history, current medications, and suitability for treatment.

We provide transparent upfront pricing from £79.00, significantly lower than typical UK market rates, with no hidden consultation fees. Our clinical team offers ongoing support throughout your treatment, so if you experience concerning side effects or have questions about your progress, you can contact our pharmacists directly on (+44) 116 4646009.

Every Wegovy pen dispensed by Cured Pharmacy is genuine UK-licensed medication sourced through regulated channels and delivered in 100% discreet packaging. Your treatment is subject to prescriber approval following clinical assessment, ensuring that Wegovy is safe and appropriate for your individual health profile. Starting your free online consultation takes under 3 minutes, with next-day delivery available across the UK for approved prescriptions.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
3. Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563 [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
6. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. If you experience severe abdominal pain, allergic reactions, or other serious symptoms while taking Wegovy, seek immediate medical attention.